The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Outcomes for elderly multiple myeloma (MM) patients often lag behind younger, transplant-eligible individuals.
• Limited data exists on the efficacy of novel agent-containing triplet regimens in older US MM patients.
• Elderly MM patients frequently present with significant comorbidities, impacting treatment tolerance and outcomes.

Purpose of the Study:

• To evaluate the outcomes of elderly, newly diagnosed, symptomatic multiple myeloma patients treated at a single US institution.
• To assess the efficacy of non-melphalan-based doublet, triplet, and quadruplet regimens, including dose-attenuated RVD.
• To compare the progression-free survival (PFS) of different initial therapeutic regimens in this patient population.

Main Methods:

• Retrospective analysis of 117 consecutive newly diagnosed MM patients aged 70 years or older.
• Evaluation of baseline characteristics, including age, comorbidities (cardiac, renal), and treatment received.
• Analysis of overall response rate (ORR), complete remission (CR), very good partial remission (VGPR), PFS, and overall survival (OS).

Main Results:

• Eighty-six patients (83%) received non-melphalan initial therapy, often with dose attenuations.
• Patients treated with dose-attenuated RVD (n=34) achieved a 94% ORR, 65% CR+VGPR, and 36-month PFS, with OS not reached.
• RVD demonstrated significantly greater PFS compared to all other regimens, including RD (P=0.030).

Conclusions:

• Dose-attenuated RVD offers particularly impressive outcomes in elderly multiple myeloma patients, including those with significant comorbidities.
• Non-melphalan triplet regimens represent a viable and effective treatment strategy for older MM patients.
• Further research into novel agent-based therapies is crucial for improving outcomes in the elderly MM population.